View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 10, 2011

Bristol-Myers and Innate Pharma to Develop Cancer Drug

Bristol-Myers Squibb and Innate Pharma have signed a licence agreement for the development and commercialisation of cancer drug IPH2102. Under the agreement, Innate Pharma will grant Bristol-Myers Squibb rights to develop, manufacture and commercialise IPH2102 and related compounds tha

By cms admin

Bristol-Myers Squibb and Innate Pharma have signed a licence agreement for the development and commercialisation of cancer drug IPH2102.

Under the agreement, Innate Pharma will grant Bristol-Myers Squibb rights to develop, manufacture and commercialise IPH2102 and related compounds that block KIR receptors.

Bristol-Myers Squibb will fund the development project with $35m, with a further $430m available depending on the achievement of pre-specified goals.

Innate Pharma has said that it will provide pre-clinical support for the development of IPH2102.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology